^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

1655P - Nampt inhibitors re-sensitize MAP17 expressing pancreas tumors

Published date:
10/16/2023
Excerpt:
...MAP17-expressing PC cells showed better response to gemcitabine, 5-FU, cisplatin and osimertinib, as well as resistance to docetaxel, bortezomib and ixazomib.